The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
NRG1 fusions in solid tumors.
 
Brinda Gupta
No Relationships to Disclose
 
Sharon Wu
Employment - Caris Life Sciences
Research Funding - Caris Life Sciences
 
Sai-Hong Ignatius Ou
Stock and Other Ownership Interests - Elevation Oncology; Turning Point Therapeutics
Honoraria - ARIAD/Takeda; BeiGene; Caris Life Sciences; Daiichi Sankyo; Dava Oncology; Johnson & Johnson/Janssen; Lilly; Pfizer
Consulting or Advisory Role - BeiGene; Daiichi Sankyo; Elevation Oncology; Janssen; Lilly; Pfizer; Takeda
Speakers' Bureau - Caris Life Sciences
Research Funding - ARIAD (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Janssen (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); Revolution Medicines (Inst); Roche Pharma AG (Inst)
 
Sourat Darabi
Honoraria - OncoLens
Consulting or Advisory Role - Bayer; BostonGene
 
Kathryn Finch Mileham
Consulting or Advisory Role - AstraZeneca; G1 Therapeutics; Genentech; Mirati Therapeutics; Regeneron; Takeda
Speakers' Bureau - Merck
 
Nishant Gandhi
Employment - Caris Life Sciences
 
Benjamin Adam Weinberg
Employment - Apple (I)
Stock and Other Ownership Interests - Apple (I)
Honoraria - Rafael Pharmaceuticals
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Bayer; DoMore Diagnostics; HalioDx; Merus NV
Speakers' Bureau - AstraZeneca; Bayer; Diiachi Sankyo; HalioDx; Lilly; Seagen; Sirtex Medical; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); Ipsen (Inst); Isofol Medical (Inst); Novartis (Inst)
Expert Testimony - AstraZeneca
Travel, Accommodations, Expenses - Boehringer Ingelheim; Caris Life Sciences; Merus NV
 
Misako Nagasaka
Consulting or Advisory Role - AstraZeneca; Caris Life Sciences; Daiichi Sankyo; EMD Serono; Genentech; Janssen; Lilly; Mirati Therapeutics; Novartis; Pfizer; Takeda
Speakers' Bureau - Blueprint Medicines; Janssen; Mirati Therapeutics; Mirati Therapeutics; Takeda
Research Funding - Tempus
Travel, Accommodations, Expenses - Anheart Therapeutics
 
Hossein Borghaei
Stock and Other Ownership Interests - Nucleai; Rgenix; Sonnet
Honoraria - Amgen; Axiom Biotechnologies; Bristol-Myers Squibb; Celgene; Daiichi Sankyo/UCB Japan; Pfizer; Regeneron
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Beigene; BioNTech; Boehringer Ingelheim; Bristol-Myers Squibb; Cantargia AB; Celgene; Da Volterra; EMD Serono; Genentech; Genmab; Guardant Health; HUYA Bioscience International; ITeos Therapeutics; Janssen Oncology; Jazz Pharmaceuticals; Lilly; Merck; Mirati Therapeutics; natera; Novartis; oncocyte; Pfizer; PharmaMar; Regeneron; Rgenix; Sonnet; Takeda
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Lilly (Inst); Merck (Inst); Millennium (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Celgene; Clovis Oncology; EMD Serono; Genentech; Lilly; Merck; Novartis; Regeneron
Other Relationship - Incyte; Novartis; SpringWorks Therapeutics; Takeda; University of Pennsylvania
 
Patrick C. Ma
Honoraria - AstraZeneca
Consulting or Advisory Role - AstraZeneca; Caris Life Sciences
Research Funding - Abbvie (Inst); Apollomics (Inst); AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Elevation Oncology (Inst); Genmab (Inst); Merck (Inst); Mirati Therapeutics (Inst); OncoC4 (Inst); Roche/Genentech (Inst)
 
Alex Patrick Farrell
Employment - Caris Life Sciences
Stock and Other Ownership Interests - Caris Life Sciences
 
George W. Sledge
Leadership - Syndax; Tessa Therapeutics
Stock and Other Ownership Interests - Pionyr; Syndax; Tessa Therapeutics
Consulting or Advisory Role - AstraZeneca; Caris Life Sciences; G1 Therapeutics; GRAIL; Synaffix; Syndax; Verseau Therapeutics
Research Funding - Genentech/Roche (Inst); Pfizer (Inst); QED Therapeutics (Inst)
Travel, Accommodations, Expenses - Caris Life Sciences; Tessa Therapeutics; Verseau Therapeutics
 
Ari M. Vanderwalde
Employment - Caris Life Sciences
Consulting or Advisory Role - Bristol-Myers Squibb; Caris Life Sciences; Compugen; Concerto HealthAI; Elsevier; Inivata
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Caris Life Sciences (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Immunomedics/Gilead (Inst); Lilly (Inst); Merck (Inst); Millennium (Inst); Replimune (Inst)
 
Wafik S. El-Deiry
Stock and Other Ownership Interests - Chimerix; Oncoceutics; p53-Therapeutics; SMURF-Therapeutics
Consulting or Advisory Role - Rain Therapeutics
Research Funding - Chimerix; D&D Pharmatech
Patents, Royalties, Other Intellectual Property - Patent on therapeutic targeting on hypoxia-inducible factors; Patent on TIC10 (ONC201); Patents pending on the use of small molecules to target mutant p53
Other Relationship - Caris Life Sciences
(OPTIONAL) Uncompensated Relationships - As above
 
Stephen V. Liu
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Candel Therapeutics; Catalyst Pharmaceuticals; Daiichi Sankyo/UCB Japan; Eisai; Elevation Oncology; Genentech; Gilead Sciences; Guardant Health; Janssen Oncology; Jazz Pharmaceuticals; Merus; MSD Oncology; Novartis; Regeneron; Sanofi; Takeda; Turning Point Therapeutics
Research Funding - Alkermes (Inst); Elevation Oncology (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Merck (Inst); Merus (Inst); Nuvalent, Inc. (Inst); RAPT Therapeutics (Inst); Turning Point Therapeutics (Inst)
Travel, Accommodations, Expenses - Caris Life Sciences